Protocol Ledger

NCT05008965 · Phase II · RECRUITING

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

Interventional Phase II clinical trial protocol NCT05008965 sponsored by Oneness Biotech Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-27 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05008965
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05008965
Protocol FieldVerified Registry Value
NCT IdentifierNCT05008965
Consolidated Lead SponsorOneness Biotech Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2021-07-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI